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Acute myeloid leukemia (AML) is a heterogeneous clonal disorder with a poor clinical outcome. 34 
Previously we showed that overproduction of reactive oxygen species (ROS), arising from 35 
constitutive activation of NOX2 oxidase, occurs in >60% of AML patients and that ROS 36 
production promotes proliferation of AML cells. We show here that the process most 37 
significantly affected by ROS overproduction is glycolysis. Whole metabolome analysis of 20 38 
human primary AML showed that blasts generating high levels of ROS have increased glucose 39 
uptake and correspondingly increased glucose metabolism. In support of this, exogenous ROS 40 
increased glucose consumption whilst inhibition of NOX2 oxidase decreased glucose 41 
consumption. Mechanistically, ROS promoted uncoupling protein 2 (UCP2) protein expression 42 
and phosphorylation of AMPK, upregulating the expression of a key regulatory glycolytic 43 
enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3). Overexpression of 44 
PFKFB3 promoted glucose uptake and cell proliferation, whilst downregulation of PFKFB3 45 
strongly suppressed leukemia growth both in vitro and in vivo in the NSG model. These 46 
experiments provide direct evidence that oxidase-derived ROS promotes the growth of leukemia 47 
cells via the glycolytic regulator PFKFB3. Targeting PFKFB3 may therefore present a new mode 48 
of therapy for this disease with a poor outcome. 49 
Significance 50 
Findings show that ROS generated by NOX2 in AML cells promotes glycolysis by activating 51 
PFKFB3, and suggest PFKFB3 as a novel therapeutic target in AML.52 
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Introduction   53 
Reactive oxygen species (ROS) are a heterogeneous group of molecules and free radicals 54 
generated as a by-product of mitochondrial oxidative phosphorylation and deliberately generated 55 
via nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) family proteins (1).  56 
In particular, NOX2 is expressed in the plasma membrane of hematopoietic cells that generates 57 
superoxide.  Superoxide rapidly dismutates to hydrogen peroxide (H2O2), a relatively long-lived, 58 
mildly reactive molecule that traverses biological membranes and mediates redox signaling in 59 
both autocrine and paracrine fashion (2).  The capacity of H2O2 to reversibly oxidise cysteine 60 
residues in regulatory domains or active sites of proteins is believed to underlie its biological 61 
effects (3).  Indeed, H2O2 plays an integral role in hematopoiesis both through direct and indirect 62 
regulation of gene expression (4).   63 
Excessive production of ROS is a common feature of cancer.  In leukemia, ROS are known to 64 
cause DNA damage (5) and also promote proliferation (6-8).  We previously showed that >60% 65 
of AML patients exhibited elevated levels of extracellular superoxide and H2O2 which correlated 66 
with NOX2 expression (6).  We also found that RAS (which is both directly and indirectly 67 
activated in AML (9)) was able to drive the production of NOX2-derived ROS in normal 68 
hematopoietic stem / progenitor cells (HSPC) and using this model we were able to show that 69 
RAS-induced ROS production contributed to the pro-proliferative effects of this oncogene (7).  70 
Despite this, the underlying mechanism through which ROS promote proliferation in cancer 71 
remains unclear.  Using this model, we show for the first time that ROS particularly impacts on 72 
genes associated with the glycolytic pathway, with a key glycolytic regulator, PFKFB3, acting as 73 
an important mediator of ROS.  Correspondingly, we show that ROS also promotes glycolysis in 74 
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cell lines and AML patient blasts.  Furthermore, myeloid leukemia cells exhibit dependency on 75 
PFKFB3 both for their growth and survival.  Given the frequently elevated levels of ROS in 76 
primary AML, these data provide a plausible mechanism for the enhanced glycolysis seen in 77 
AML and suggest that a therapeutic opportunity exists in which agents inhibiting PFKFB3 could 78 
be used to treat this disease. 79 
Materials and Methods 80 
Key resources 81 
All reagents and key resources are provided in Supplemental material. 82 
Primary cell material and cell culture 83 
For whole cell metabolomics, a subset of bone marrow samples (n=20) from AML patients who 84 
had enrolled in UK MRC/NCRI AML clinical trials at point of diagnosis, before treatment and 85 
obtained informed written consent from patients in accordance with the 1964 Declaration of 86 
Helsinki, was used.  Control mononuclear cells were isolated from peripheral blood of human 87 
male/female volunteers (n=6).   88 
Human neonatal cord blood was obtained from healthy full-term pregnancies at the University 89 
Hospital Wales, Cardiff, UK.  These were obtained with informed consent and with approval 90 
from the South East Wales Research Ethics Committee in accordance with the 1964 Declaration 91 
of Helsinki.  Human CD34+ cells (>95% pure, which constitute a mixed progenitor blood cell 92 
population) were isolated, cultured and transduced with retroviral vectors based on the PINCO 93 
backbone harboring either a GFP or DsRED selectable marker as previously described (10). 94 
Transduced human CD34+ hematopoietic progenitor cells were cultured in supplemented IMDM 95 
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as previously described (10) containing 20% v/v FCS; supplemented with 5 ng/mL human (hu) 96 
IL-3, huG-CSF and huGM-CSF and 20 ng/mL huSCF.  For microarray studies, on day 5 of 97 
culture (post CD34+ isolation), cells were washed in PBS and resuspended in supplemented 98 
IMDM in the presence or absence of 100nM diphenyleneiodonium (DPI) for 18 h prior to 99 
Affymetrix microarray (n=4).  RNA was extracted using Trizol® as previously described (11).  100 
Due to the high frequency of retroviral transduction (~70%), enrichment of transduced cells was 101 
unnecessary.  102 
Cell lines were purchased from ATCC or ECACC and cultured according to recommended 103 
conditions at 37oC, 5% CO2 for all experiments.  All lines are maintained at ≤ 20 passage from 104 
receipt.  The genetic identity of the cell lines was confirmed by short tandem repeat (STR) at 105 
purchase.  Monthly monitoring for Mycoplasma contamination was performed and confirmed 106 
using the MycoAlert Detection Kit (Sigma).  Mice were bred and maintained at Cardiff 107 
University (UK) and were cared for in accordance with Institutional Animal Care and Use 108 
Committee guidelines.  NOD-SCID IL2R(-/-)(NSG) female mice were sub-lethally irradiated 109 
with 200cGy total body irradiation 24h before inoculation of THP-1 cells via tail-vein injection.  110 
Transplanted cells were analysed using hCD45-FITC, hCD33-APC and mCD45-PerCP-Cy5.5 by 111 
flow cytometry.  For ex vivo analysis of mouse MRP8 N-RASG12D leukemia (12), bone marrow 112 
was harvested from the tibias and glucose uptake was measured using 2-NBDG as described 113 
below.  114 
Detection of superoxide 115 
Following gene transduction, the indicated cell cultures were adjusted for viable cell number and 116 
superoxide measurement was carried out using the chemiluminescent probe DiogenesTM 117 
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(Geneflow, U.K.).  Briefly, cells were resuspended in their conditioned medium to a density of 118 
1x106 cells/mL and 150 µL aliquots were assayed in triplicate in FluoroNunc Maxisorp 96 well 119 
plates (Thermo-Fisher Scientific, Loughborough, UK). Diogenes (50 L) was added 120 
immediately prior to recording chemiluminescence as previously described (7).   121 
 122 
Determination of glucose and lactate  123 
Supernatant from the culture media was filtered using Microcon-10 kDa centrifugal filter units 124 
(Merck-Millipore, Feltham, UK) at 12,782 × g for 30 min. The levels of D-glucose and L-125 
Lactate were measured by fluorimetry using a glucose and L-Lactate assay kit (Abcam, 126 
Cambridge, UK) coupled with a Chameleon Hidex fluorescent plate reader (Ex/Em 535/590 nm), 127 
according to the manufacturer’s instructions.  Briefly, samples were diluted with proprietary 128 
glucose or lactate buffer to a volume of 50μL and added in triplicate to a black 96 well flat 129 
bottomed microclear plate (Greiner Bio-One, Stonehouse, UK).  Glucose or lactate buffer 130 
containing proprietary glucose or lactate probe (0.8% v/v) and proprietary glucose or lactate 131 
enzyme mix (0.8% v/v) were added (50μL) to each well and left to incubate in the dark at RT for 132 
30 min.  Fluorescence was measured (Ex/Em 535/590nm) and compared with glucose or lactate 133 
standards assayed in duplicate on the same plate.  134 
To determine cellular glucose uptake at the individual cell level, the glucose bioprobe 2-NBDG 135 
(Life Technologies, U.K.) was employed in conjunction with flow cytometry.  Cells were 136 
washed twice in PBS then treated with 2-NBDG (10μM) or PBS alone (to establish a 137 
background control) followed by incubation for 10 min (37oC, 5% CO2) and two washes in ice 138 
cold PBS.  Cells were immediately analysed by flow cytometry using an Acurri C6 flow 139 
cytometer. 2-NBDG emits fluorescence at a wavelength of 542nM.  Having excluded cell debris 140 
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based on FSC/SSC, the median glucose uptake per cell of the samples was established by 141 
subtracting the median value of fluorescence of the background control cells from the median 142 
value of fluorescence of the cells treated with 2-NBDG. In some experiments, cells were treated 143 
with PEGylated catalase (300 mU/mL) for 24 h at 37oC, prior to analysis of glucose uptake.  144 
Expression analysis 145 
Transduced CD34+ cells were washed in PBS and resuspended in supplemented IMDM in the 146 
presence or absence of 100nM diphenyleneiodonium (DPI) for 18 h prior to RNA isolation (n=4) 147 
as previously described (11).  RNA was hybridized to Affymetrix GeneChip® Human Exon 1.0ST 148 
Array for whole-transcript expression analysis.  Data were analysed using Partek Genomics Suite 149 
(v6.6; Partek, MO, USA).  Data analysis of CEL files are described in Supplemental Methods; 150 
data available at https://www.ebi.ac.uk/arrayexpress (accession number e-mexp-583). Gene 151 
Ontology (GO) enrichment analysis was undertaken using Metacore® (Clarivate Analytics, 152 
U.K.). 153 
Detection of each protein was determined by western blot using antibodies described in 154 
Supplemental Methods, in conjunction Amersham ECL™ Advance/Prime Western Blotting 155 
Detection Kit (GE Healthcare U.K.). 156 
Metabolomics 157 
Metabolomic analysis of AML patient blast samples or Mv4;11 was carried out by MetabolonTM 158 
(http://www.metabolon.com/).  Data was generated using ultra-high performance liquid 159 
chromatography-tandem mass spectroscopy (UPLC-MS/MS) and gas-chromatography mass-160 
spectroscopy (GC-MS).  Peripheral blood and bone marrow samples collected from a random 161 
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cohort of AML patients were counted and analysed for viability using 7-AAD.  Only those 162 
samples with a cell count greater than 30 million and a viability greater than 80% were sent for 163 
analysis by MetabolonTM (n=20).  Additionally, mononuclear cells isolated from healthy 164 
individuals (n=6) were also sent to MetabolonTM as a comparative control. DiogenesTM analysis 165 
of AML blasts stratified the patient samples into ROSHigh (above median) and ROSLow (below 166 
median).  Raw data was extracted, peak identified and quality control processed using 167 
proprietary MetabolonTM hardware, software and biochemical library database.  Following 168 
normalisation to Bradford protein concentration, log transformation and imputation of missing 169 
values with the minimum observed value for each compound, Welch’s unequal variance two 170 
sample t-test was performed to identify significant differences between the experimental groups. 171 
To account for a potentially high false discovery rate (as a consequence of multiple 172 
comparisons), a q-value was also calculated, where a lower q-value is an indication of higher 173 
confidence in the result. 174 
Protein expression analysis of genes identified by microarray analysis 175 
Detection of each protein (see key resources table) was determined using a monoclonal or 176 
polyclonal antibody in conjunction with an anti-mouse or anti-Rabbit HRP linked secondary 177 
antibody and Amersham ECL™ Advance/Prime Western Blotting Detection Kit (GE Healthcare 178 
UK) according to the manufacturer’s instruction.  In the case of NOX2 or glucose transporter cell 179 
surface protein expression, PE conjugated antibody to NOX2 epitope or an indirect stain coupled 180 
with anti-mouse IgG-APC was used and protein expression was determined by flow cytometry.  181 
Flow cytometric and data analysis  182 
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Flow cytometric data were acquired using an Accuri C6 cytometer (BD, U.K.).  Data analysis 183 
was performed using FCS express v6 (DeNovo Software).  The threshold for GFP positivity was 184 
determined from the autofluorescence of GFP/DsRED negative cells in mock transduced 185 
cultures.  Significance of difference was tested using Minitab software version 19 (Minitab Inc, 186 
PA) all analyses except those provided by Metabolon assays (see above).  Appropriate statistical 187 
tests used are labelled in figure legends.  To better understand variations between samples, 188 
principal component analysis (PCA) or hierarchical clustering using distance Pearson Correlation 189 
was employed to provide a global analysis of how closely related or otherwise any given sample 190 
is (mRNA or biochemical).  191 
Results 192 
NOX-derived ROS promotes transcriptional change in N-RASG12D expressing 193 
hematopoietic progenitor cells and AML patient blasts 194 
We previously showed that expression of N-RASG12D in HSPC strongly promotes ROS 195 
production through activation of NOX oxidases l ading to increased proliferation (7).  We used 196 
this model of ROS overproduction in primary hematopoietic CD34+ cells (Supplemental Fig. 197 
S1A-E) to investigate the changes in gene expression mediated by ROS.  We reasoned that we 198 
could enrich for ROS target genes by looking for gene changes which were absent in mutant N-199 
RASG12D cells treated with the NOX inhibitor, DPI (Fig. 1A).  N-RASG12D significantly changed 200 
the expression of 305 genes in HSPC (p<0.05) (Supplemental Table S1) of which 24 were 201 
specifically attributed to ROS production.  MetacoreTM pathway analysis identified glycolysis as 202 
the most dysregulated pathway (Fig. 1B).  ROS significantly impacted the expression of 18% of 203 
genes involved in carbohydrate metabolism (Fig. 1C).  To examine this in AML patient blasts, 204 
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we analyzed the TCGA database of 161 AML patients using cBioPortal (13, 14).  Hierarchical 205 
clustering in Fig. 1D shows that patients with high NOX2 (CYBB) expression (which we have 206 
previously shown to correlate with ROS production (7)) clustered together based on correlative 207 
expression of genes involved in carbohydrate metabolism suggesting changes in glucose 208 
utilization compared to those patients with lower NOX2 expression; more than half the ROS 209 
regulated genes observed above are seen in this cluster.  Fig. 1E shows the ROS-responsive 210 
genes that significantly correlated with NOX2 expression in AML blasts.  Data derived from 211 
TCGA (15) supports the overexpression of NOX2 mRNA in AML (Supplemental Fig. S2A).  212 
Increased NOX2 expression also showed a trend towards poor prognosis (P=0.075; Supplemental 213 
Fig. S2B).  We did not observe any significant association of expression of genes identified in 214 
Fig.1E with AML cytogenetics or survival.  Taken together, these data show that NOX inhibition 215 
upregulates the expression of genes involved in carbohydrate metabolism. 216 
ROS promotes functional changes in glucose uptake 217 
Increased aerobic glycolysis is a common feature of cancerous cells with concomitant increases 218 
in cellular glucose uptake and lactate secretion (16).  In order to assess whether transcriptional 219 
changes observed above resulted in functional glycolytic changes, glucose uptake and lactate 220 
secretion were measured.  The level of glucose taken up by N-RASG12D HSPC was significantly 221 
more (48±19%) when compared to control (Fig. 2A) when analysing glucose remaining in the 222 
culture media.  To confirm that these changes in cellular glucose consumption occurred at the 223 
single cell level, the fluorescent glucose bioprobe 2-NBDG was employed (Supplemental Fig. 224 
S3).  N-RASG12D increased glucose uptake by 36±15% compared to controls (Fig. 2A).  To 225 
support these in vitro data, glucose uptake was assayed ex vivo in bone marrow cells harvested 226 
from secondary transplants of transgenic mice expressing N-RASG12D (12).  A significant 227 
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90±48% increase in glucose uptake was observed in N-RASG12D mice compared to wild type 228 
control (Fig. 2B).  These data demonstrate that expression of mutant N-RASG12D increases 229 
glucose uptake both in vitro and ex vivo. 230 
To assess whether increases in glucose uptake were mediated by NOX-derived ROS, we 231 
examined the effect of the NOX inhibitor, DPI, on N-RASG12D HSPC.  NOX inhibition reduced 232 
glucose uptake by 20% compared to untreated cells (Fig. 2C) when analysing glucose remaining 233 
in the culture media.  Similar data were obtained with the alternative NOX inhibitor, VAS-2870 234 
(17).  Treatment with PEGylated catalase (which catabolises the destruction of H2O2 at the 235 
plasma membrane (18)) also reverted the increase in glucose uptake (Fig. 2C).  In contrast, 236 
treatment of control HSPC with DPI or VAS-2870 had no significant effect on glucose uptake.  237 
To determine whether these changes in glucose uptake resulted in increases in extracellular 238 
lactate production, levels of L-lactate in the culture supernatant were assayed.  Interestingly, no 239 
significant changes in lactate secretion (see below) was observed in cells expressing N-RASG12D 240 
compared to control (Fig. 2D).   241 
Overproduction of ROS is associated with changes in glucose utilization in primary AML 242 
blasts 243 
The above data suggests increased glucose uptake is at least in part mediated by production of 244 
NOX-derived ROS.  To establish evidence for this in primary AML, we stratified AML blasts 245 
according to extracellular ROS production (ROSHigh and ROSLow; Supplemental Fig. S4A-B) and 246 
analysed the global biochemical metabolomic profile.  Using this approach, 444 named 247 
metabolites were identified which distinguished ROSHigh, ROSLow and control MNC by PCA 248 
(Fig. 3A).  A summary of the biochemicals that achieved statistical significance (p≤0.05) or 249 
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approached it (0.05<p<0.10), is shown in Fig. 3B and in full in Supplemental Table S2.  Random 250 
Forest (RF) analysis of the cellular metabolic profiles resulted in 85% predication accuracy in 251 
differentiating ROSHigh and ROSLow groups (Supplemental Fig. S5).  Among the 30 top-ranking 252 
metabolites resulting from the RF analyses were biochemicals spanning different pathways, but 253 
primarily limited to those associated with nucleotides and lipid metabolism.  Polyunsaturated 254 
fatty acids and lipid-related changes in n3 and n6 polyunsaturated fatty acids showed significant 255 
accumulations within the AMLHigh compared to the AMLLow samples which would be indicative 256 
of increased uptake (Supplemental Table S2).  Interesting, within the AMLHigh samples, 257 
lysolipids, monoacylglycerols and glycerol were consistently and significantly higher in relation 258 
to AMLLow ROS (see discussion).     259 
Focussing specifically on detected metabolites within the glycolytic pathway, we found, glucose, 260 
glucose-6-phosphate and fructose-6-phosphate levels were significantly higher within the 261 
ROSHigh blasts compared to ROSLow blasts indicating that increased glucose utilisation correlates 262 
with elevated ROS (Fig. 3C).  In agreement with our in vitro HSPC model, changes in lactate 263 
were not significantly different between the ROS high and ROS low groups but were higher than 264 
the control MNC (Fig. 3C).  This suggests that whilst glucose utilisation is increased in primary 265 
AML, higher levels of ROS are consistent with increased levels of glycolytic intermediates.  266 
Indeed, metabolites associated with the pentose phosphate pathway (PPP) including the isobaric 267 
compound ribulose/xylulose 5-phosphate and sedoheptulose-7-phosphate were also higher in 268 
ROSHigh vs ROSLow samples (Fig. 3D).  We next set out to determine whether the addition of 269 
exogenous H2O2 to the ROS
Low AML cell line, Mv4;11 could itself promote changes in glucose 270 
metabolism.  Similarly to primary AML-ROShigh we observed an increase in glucose 271 
consumption (Fig. 4) and biochemicals associated with the PPP (Supplemental Fig. S6A and B).  272 
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Taken together these data suggests increased glucose utilization by PPP, potentially driving 273 
nucleotide biosynthesis and NAD(P)H generation within ROSHigh blasts.   274 
PFKFB3 is a ROS responsive target that mediates changes in glucose utilization  275 
The data above suggest that ROS-induced changes in mRNA expression of genes of glycolysis 276 
(Fig. 1C) was associated with altered glucose utilization (Fig. 3).  To validate these findings, we 277 
surveyed the expression of these ROS-responsive genes at the protein level (Supplemental Fig. 278 
S7A-D).  ROS induced changes at the protein level, only occurred in the expression of the 279 
regulatory glycolytic enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 280 
(PFKFB3)(Fig. 4A and Supplemental Fig. S7A).  PFKFB is a bifunctional enzyme with both 281 
kinase and phosphatase activity that regulates the glycolytic pathway (19).  To support this data, 282 
we inhibited NOX derived ROS production in the ROSHigh AML cell line, THP-1, using NOX2 283 
knock-down (Supplemental Fig. S8A-C).  In line with our previous data (7), NOX inhibition 284 
with DPI suppressed proliferation of N-RASG12D cells.  As shown in Fig. 4B, loss of NOX2 285 
protein expression and ablation of superoxide production in these cells reduced the expression of 286 
PFKFB3 compared to control cells with a concomitant reduction in proliferation by 30±12% 287 
when compared to control (Fig. 4C).  Glucose uptake was similarly reduced by 25±17% (Fig. 288 
4D).  We next set out to determine whether the addition of exogenous H2O2 to the ROS
Low AML 289 
cell line, Mv4;11 cells, could itself promote PFKFB3 protein expression.  As predicted, we 290 
observed a dose-dependent increase in PFKFB3 protein expression (Fig. 4E) with concomitant 291 
increases in proliferation (Fig. 4F and Supplemental Fig. S9) and glucose uptake (Fig. 4G). 292 
To investigate whether PFKFB3 itself could mediate these phenotypic changes, we 293 
overexpressed PFKFB3 in Mv4;11 cells (PFKFB3-OE; Fig. 5A).  Cells overexpressing PFKFB3 294 
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showed a 72±30% increase in proliferation (at 72 h) compared to control cells (Fig. 5B) and 295 
correspondingly showed an increased proportion of cells in S+G2M phase of the cell cycle 296 
(Supplemental Fig. S10A).  The levels of glucose uptake in PFKFB3-OE cells were significantly 297 
more (35±2%) compared to control cells (Fig. 5C).  To determine the impact of decreased 298 
expression of PFKFB3 in ROS generating cells, PFKFB3 was knocked-down in THP-1 cells 299 
(Fig. 5D).  Knock-down of PFKFB3 resulted in reduced proliferation of these cells (Fig. 5E) and 300 
a reduction in the percentage of cells in cycle (Supplemental Fig S10B), though without 301 
detectable change in glucose uptake in this context (Fig. 5F).  These experiments provide the 302 
first direct evidence that PFKFB3 controls the growth of leukemia cells which is consistent with 303 
cells producing high levels of ROS.  304 
ROS induced changes in PFKFB3 expression are mediated via UCP/p-AMPK  305 
To determine the mechanism of ROS induced PFKFB3 expression we analysed two potential 306 
mechanisms.  Firstly, HIF-1α has been shown to induce increased PFKFB3 mRNA expression 307 
(20).  Analysing our transcriptome data revealed that HIF-1 is a strongly ROS-responsive gene 308 
(Fig. 6A).  However, we were unable to detect expression of HIF1- protein regardless of NOX2 309 
status (Fig. 6B).  Furthermore, HIF1 knock-down (Fig. 6B) did not change PFKFB3 protein 310 
expression (Fig. 6C) or glucose uptake (Fig. 6D).  Collectively, these data do not therefore 311 
support a role of HIF1- in mediating glycolytic changes in these cells. 312 
Superoxide levels are sensed by uncoupling protein 2 (UCP2) which drives an adaptive response 313 
to protect against oxidative stress including the activation of AMP-activated protein kinase 314 
(AMPK) (21) leading to increased production of PFKFB3 (22).  In accord with this we observed 315 
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that treatment of the ROSLow AML cell line, Mv4;11, with exogenous H2O2 increased both 316 
PFKFB3 expression and AMPK phosphorylation (Fig. 6E).  This induction was inhibited by 317 
Genipin (which specifically inhibits UCP2 expression (23)) decreasing both p-AMPK and 318 
PFKFB3 levels (Fig. 6D) and concomitant reduction in glucose consumption (Fig. 6F).  To 319 
confirm, changes in p-AMPK/mTOR signalling, we next examined downstream signalling of 320 
mTOR by western blot.  As shown in Supplemental Fig. S11A and B phosphorylation of S6 321 
kinase is decreased following treatment with H2O2; an effect reversed when UCP2 is inhibited.  322 
These data support a role for UCP2 having a pivotal role in mediating ROS-induced changes in 323 
the expression of PFKFB3. 324 
Targeting PFKFB3 reduces glucose uptake and cell proliferation in AML cells  325 
We next wanted to establish whether chemical inhibition of PFKFB3 could have the potential for 326 
a therapeutic impact in the treatment of AML.  Having established appropriate inhibitory 327 
concentrations of two chemical inhibitors of PFKFB3, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-328 
1-one (3PO) (24) and the more specific PFK158 (25) (Supplemental Fig. S12A-C).  We next 329 
treated ROSHigh cells (THP-1) with 3-PO or PFK158 which resulted in a reduction in glucose 330 
uptake (Fig. 7A and B).  Correspondingly, treatment with 3PO resulted in a significant dose 331 
dependent decrease in proliferation of THP-1 cells (Fig. 7C) whilst treatment with the more 332 
specific PFK158 (25) also significantly reduced proliferation at doses >500nM (Fig. 7D).  We 333 
next investigated whether PFKFB3 inhibition could suppress the effects of exogenous ROS on 334 
the ROSLow cell line Mv4;11.  No change in viability in Mv4;11 (or THP-1) cells treated with 335 
3PO, PFK158 or H2O2 were observed.  Treatment of Mv4;11 cells with H2O2 resulted in a 336 
20±9% increase in glucose uptake compared with control (as expected), whilst combined 337 
treatment with H2O2 and 3PO or with PFK158 inhibitor ablated the response to peroxide (Fig. 338 
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7E).  Treatment with these inhibitors alone did not alter glucose uptake when compared to 339 
control cells.   340 
Finally, we investigated whether loss of PFKFB3 also affected leukemia growth in vivo.  Knock-341 
down of PFKFB3 expression in THP-1 cells resulted in a significant reduction (83%) of 342 
leukemia cell growth, supporting a role of PFKFB3 in the proliferation of AML cells in vivo 343 
(Fig. 7F).  Overall these experiments provide the first direct evidence that oxidase-derived ROS 344 
promotes the growth of leukemia cells via PFKFB3 expression and suggests a potential ROS-345 
dependent mechanism for these changes. 346 
Discussion 347 
Whilst increased levels of ROS produced by AML blasts or tumor cells have been shown to 348 
induce double strand breaks (26), they also promote proliferation (6, 27).  Here we present 349 
evidence that the proliferative response to ROS is supported by changes in glucose uptake and 350 
altered glucose metabolism.  Furthermore, we demonstrate that AML cells exhibit enhanced 351 
PFKFB3 expression and that inhibitors that target the function of this protein (or its upstream 352 
pathway UCP2/AMPK) may provide a tractable therapeutic target in AML.  353 
ROS are now recognized as important secondary messengers, serving as critical cell signaling 354 
molecules through the capacity of H2O2 to reversibly oxidise cysteine residues (28).  Using a 355 
primary cell model for ROS production, we investigated the effect of ROS on gene transcription 356 
and found that changes in mRNA expression were associated with enzymes involved in glucose 357 
metabolism.  Specifically, we identified several gene changes associated with glycolysis coupled 358 
with increased cellular glucose uptake.  This is consistent with many solid tumor models that 359 
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shift energy production from oxidative phosphorylation toward the less efficient glycolytic 360 
pathway, a phenomenon known as the Warburg effect (29).  Indeed, our previous data have 361 
shown no significant differences in mitochondrial ROS were observed in mutant Ras expressing 362 
CD34+ cells compared to controls (7).  Using inhibitors to NOX2, we were able to attribute the 363 
effects of observed increases in glucose uptake to the production of extracellular NOX2-derived 364 
ROS.  Additionally, we found leukemic cell lines increased glucose uptake in response to 365 
exogenous ROS or showed decreased uptake following NOX2 knock-down.  We show for the 366 
first time that the effect of ROS on glucose uptake is mediated by PFKFB3 (see below).  367 
However, pro-glycolytic effects of ROS on other genes have been observed (30) and is 368 
consistent with increased glycolysis in solid tumor models associated with GLUT upregulation 369 
(31).  370 
In the context of primary AML, we previously demonstrated that >60% of patients exhibited 371 
high levels of ROS which correlated with NOX2 expression (6).  Here, AML blasts stratified 372 
according to level of extracellular ROS production were analysed by global biochemical 373 
metabolomic profiling.  Several hundred metabolites were identified which distinguished 374 
patients according to ROS production including metabolite levels within the glycolytic pathway 375 
(glucose, glucose-6-phosphate and fructose-6-phosphate) suggesting that the impact of ROS is to 376 
increase the levels of glycolytic intermediates, primarily those in the early part of the glycolytic 377 
pathway.  In support of this, metabolites associated with the PPP such as sedoheptulose-7-378 
phosphate and the isobaric compounds ribulose/xylulose 5-phosphate were also elevated in 379 
ROSHigh samples.  These data may be indicative of a reprogramming of metabolic pathways, 380 
where increased glucose consumption, is metabolised via the PPP, resulting in increased 381 
generation of NADPH (to counter oxidative stress) and biosynthetic precursors such as 382 
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nucleotides, necessary for cell growth and DNA repair.  Interestingly, metabolomic profiling of 383 
serum from AML patients has also revealed distinct increases in the glycolytic metabolic (32, 384 
33).  Additionally, NOX2 expression has previously been demonstrated to regulate self-renewal 385 
of leukemic stem cells (34).  Using a murine model of leukemia, Adane et al showed that 386 
suppression of NOX2 expression led to increased fatty acid oxidation and potential limiting of 387 
substrates passing through glycolysis.  Our study supports this notion, where we also observed 388 
significant changes associated with lipid metabolism in human AML; lipid-related changes in n3 389 
and n6 polyunsaturated fatty acids showed significant accumulations within the AMLHigh in 390 
relation to the AMLLow samples.  The higher levels of monoacylglycerols and glycerol in the 391 
AML High samples may also be an indicator of increased lipolysis to support free fatty acid levels.  392 
Taken together, these data show that NOX2 derived ROS impact on glucose metabolism, an 393 
effect consistent with that seen in solid tumors (35). 394 
We identified significant ROS induced changes in mRNA and in protein of the regulatory 395 
glycolytic enzyme PFKFB3.  PFKFB3 mRNA expression has been shown to be upregulated in 396 
several solid tumors including colon, breast, prostate, ovary, thyroid and head and neck 397 
squamous cell carcinoma (36, 37).  Whilst PFKFB3 mRNA is elevated in AML we did not 398 
observe any significant association of expression with particular AML subgroups or clinical 399 
outcome.  PFKFB is a bifunctional enzyme, which catalyses both forward and reverse reaction of 400 
F-6-P to F-2,6-BP (19).  In turn, F-2,6-BP is a powerful allosteric activator of PFK which 401 
catalyses F-6-P to F-1,6-BP, a rate limiting step in glycolysis.  The PFKFB3 isoform contains a 402 
lysine and serine at position 79 and 80 respectively (38) resulting in increased kinase activity, 403 
which is 740 times greater than other PFKFB isoforms, making it a powerful driver of glycolysis 404 
(39).  Here we also showed ROS dependent changes in PFKFB3 expression in AML lines with 405 
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constitutive NOX2 activity/ROS production coupled with suppression of reduction in 406 
proliferation and glucose uptake upon ROS inhibition.  Overexpression/knock-down of PFKFB3 407 
generated the predicted changes in glucose uptake and cell proliferation in vitro whilst knock-408 
down of PFKFB3 strongly suppresses leukemia growth in vivo (though we have not confirmed 409 
what the mechanistic basis of the effects are, in vivo data).   410 
It has previously been established that ROS can regulate HIF-1 in a non-hypoxic pathway (40).  411 
Further, stabilisation of HIF-1α has been associated with increased expression of glycolytic 412 
genes, including PFKFB3 (41, 42).  Our data showed increased expression of HIF-1α mRNA 413 
correlated with increased ROS levels.  However, immunoblotting showed that HIF-1α was not 414 
expressed at detectable levels and furthermore knock-down of the mRNA for this protein did not 415 
result in any changes in glucose uptake.  ROS has also previously been shown to activate 416 
mitochondrial proteins (UCP2) to regulate the leak of protons across the inner membrane, 417 
resulting in poor fuel conversion efficiency and a more pro-glycolytic phenotype including 418 
AMPK activation (21).  We show that inhibition of UCP2 led to decreased p-AMPK and 419 
PFKFB3 levels.  Further, analysis of the mTOR pathway showed decreased S6-Kinase 420 
expression in response to ROS which was reverted upon UCP inhibition.  AMPK is a master 421 
regulator of cellular energy homeostasis, upregulating catabolic metabolic processes including 422 
increased glycolytic flux and protects against ROS accumulation by increasing NADPH 423 
production (see below) (17).  AMPK has previously been shown to be activated via ROS (43), in 424 
addition to regulating glycolysis and PFKFB3 expression in a phosphorylation dependent 425 
manner in cancer cells (22, 44).  Domenech t al., have shown that mitotic arrest of cancer cells 426 
leads to altered energy requirements through switching to a more glycolytic phenotype and 427 
increased AMPK phosphorylation (22).  This suggests that PFKFB3 could also be increased 428 
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through changes to cell cycle or autophagy.  Metabolomic data generated as part of this study 429 
also indicated increased levels of ROS correlated with an increase in fatty acid metabolites 430 
(Supplemental Table S2).  Interestingly, changes in expression of UCP2 has been linked with 2-3 431 
fold elevation of plasma fatty acids reviewed in (45).  Further, activation of fatty acid 432 
metabolism by AMPK (46) is interesting given that ROS activation of AMPK has also been 433 
shown to potentially influence and maintain HSC (47).  Conversely, inhibition of mitochondrial 434 
fatty acid oxidation induces loss of HSC maintenance (48). 435 
Identification of metabolic differences between normal and malignant tissue creates a therapeutic 436 
opportunity for targeting of glycolysis in the treatment of AML; the potential for targeted therapy 437 
in AML, through reduction of aberrant metabolic activity via inhibition of 6-phosphogluconate 438 
dehydrogenase (6-PGD) function has also recently been shown (32).  The therapeutic potential of 439 
PFKFB3 inhibition (e.g. PFK158) (25) in cancer is currently undergoing phase I clinical trials 440 
(49).  Consistent with studies in solid tumors (50, 51), data presented here shows that in ROSHigh 441 
AML cells, treatment with PFKFB3 inhibitor significantly reduced glucose uptake and also 442 
proliferation both in vitro and in vivo.  This supports a previous study which showed chemical 443 
inhibition of PFKFB3 in Jurkat T-cell leukemia cells results in decreased proliferation and 444 
glucose uptake (24).  In myeloproliferative neoplasms expressing JAK2 mutations, PFKFB3 is 445 
required for increased growth and metabolic activity, an effect blocked by targeted knock-down 446 
of PFKFB3.  This study therefore suggested that therapies specifically blocking PFKFB3 447 
activity/expression would be expected to inhibit JAK2/STAT5-dependent malignancies (52).   448 
In conclusion, this and previous data suggest that production of ROS may confer a competitive 449 
advantage on premalignant/malignant cells by promoting the proliferation of these cells via 450 
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changes to carbohydrate metabolism.  We show for the first time a link between increased NOX-451 
derived ROS production and increased expression of the key glycolytic regulatory enzyme, 452 
PFKFB3.  Furthermore, PFKFB3 inhibitors or genetic knock-down established a causal link 453 
between ROS production, cellular glucose uptake and PFKFB3 activity.   454 
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Figure Legends 613 
Figure 1.  NOX-derived ROS promotes transcriptional change in N-RASG12D expressing 614 
HSPC and AML patient blasts and identifies the glycolytic pathway as a major target of 615 
ROS.  (A) Summary flow diagram showing the strategy for changes in mRNA expression 616 
analysed by Affymetrix microarray.  Four treatment conditions were employed for the 617 
examination of the effect of N-RASG12D and ROS on mRNA gene expression: CD34+ HSPC 618 
infected with control vector (‘C’) or N-RASG12D (‘N’), incubated in the presence or absence of 619 
100nM DPI for 24 h to determine the ROS-specific gene expression profile (n=4).  We examined 620 
changes that were only co-directional (i.e. they were similarly dysregulated in each replicate).  621 
(B) Significantly changing GeneGoTM Maps in human HSPCs as a response to changes in 622 
exposure to ROS.  (C) Statistically significant changes in mRNA showing the impact of DPI 623 
(unfilled bars) on N-RASG12D dependent target gene expression (filled bars).  Non-specific 624 
effects of DPI were excluded as described in (A).  Only genes involved in carbohydrate 625 
metabolism using the Human Exon 1.0ST Full Probe Set list were analysed.  Statistically 626 
significant gene changes in Control cells treated with DPI compared to untreated control were 627 
excluded from the final list.  Data represents mean fold change of n=4; P value calculated by 2-628 
way ANOVA with Bonferroni multiple testing correction.  (D) Hierarchical clustering of patient 629 
AML mRNA expression z-Scores based on RNA Seq V2 RSEM.  NOX2 high / low expressing 630 
blasts was defined as, above and below the median expression intensity of NOX2 (aka CYBB).  631 
Genes involved in glycolysis and carbohydrate transport are shown (as defined by Affymetrix 632 
NetaffxTM gene annotation software under advanced pathway searches); AML patient blasts 633 
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(n=160).  Boxed section shows cluster of genes associated with NOX2 high AML blasts.  (E) 634 
Expression of genes from AML patient blasts significantly correlating with NOX2 (CYBB, 635 
R>0.5) expression.  R; Spearmans Correlation co-efficient.  FDR, False Discovery Rate; GLUT3 636 
(SLC2A3), glucose transporter 3; GLUT5 (SLC2A5), glucose transporter 5; GLUT6 (SLC2A6), 637 
glucose transporter 6; GLUT14 (SLC2A14), glucose transporter 14; HK, hexokinase; PFKFB, 6-638 
phosphofructo-2-kinase/fructose-2,6-biphosphatase; PFK(P). phosphofructokinase platelet; 639 
FBP1, fructose-1,6-bisphosphatase 1; ENO, enolase; PK(M), pyruvate kinase muscle; LDH(A), 640 
lactate dehydrogenase A; MCT4 (SLC16A3), monocarboxylate transporter 4. 641 
Figure 2. ROS promotes glucose uptake.  (A) ‘Medium’ - following transduction, N-RASG12D 642 
were cultured for 3 days without growth factors, glucose present in the media was assayed using 643 
a fluorometric glucose kit (n=4) (see methods) and normalised to empty-vector control.  Glucose 644 
uptake in the cell is inversely proportional to the glucose remaining in the media.  ‘2-NBDG’ - 645 
glucose uptake using the fluorogenic substrate 2-NBDG (normalised to control) in N-RASG12D 646 
HSPC (n=4) cultured as above.  (B) Glucose uptake (normalised to Wild Type (WT) control) ex 647 
vivo in N-RASG12D bone marrow compared to WT control cells (n=8).  (C) N-RASG12D HSPCs 648 
(day 5 post infection) were treated with 100nm DPI and cultured for 24 h without growth factors.  649 
Glucose in culture media (normalised to untreated control) was assayed (n=3).  Glucose uptake 650 
in the cell is inversely proportional to the glucose remaining in the media.  N-RASG12D HSPCs 651 
were treated with 5M VAS-2870 (VAS; n=3) or 300mU/mL PEGylated catalase (Cat; n=2) for 652 
24 h and glucose uptake assayed using 2-NBDG (normalised to PEG-treated control).  (D) 653 
Concentration of extracellular L-lactate in culture media of transduced CD34+ cells (cultured as 654 
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above) treated with 5 M VAS-2870 as above (n=4).  Data represents mean±1SD.  * denotes 655 
p<0.05 and ** p<0.001 analysed by one sample t-test. 656 
Figure 3.  Overproduction of ROS is associated with changes in glucose utilizations in 657 
primary AML blasts.  Data from global biochemical profiling of AML blasts stratified 658 
according to extracellular ROS production was performed.  (A) Principal components analysis of 659 
global biochemical profiling of AML cells with high and low ROS production; ROSLow, n=10; 660 
ROShigh, n=10.  Also shown are normal human mononuclear control cells (Ctrl_MN: n=4).  (B) 661 
Summary of the numbers of biochemicals that achieved statistical significance (*p≤0.05), as well 662 
as those approaching significance (##0.05<p<0.10) analysed by Welch’s two sample t-test.  663 
Levels of biochemicals normalised to total protein in (C) glycolysis and (D) Pentose Phosphate 664 
Pathway (PPP) are shown.  665 
Figure 4. PFKFB3 protein expression correlates with levels of NOX2 derived extracellular 666 
ROS.  (A) Human CD34+ HSPC control and N-RASG12D (day 5 post transduction) were cultured 667 
for 24 h in cytokine free media in the presence or absence of DPI (100nM) followed by whole 668 
cell protein extraction.  (i) Example western blot of PFKFB3 protein expression.  (ii) Relative 669 
protein expression (as measured by pixel densitometry of equivalent regions of interest (ROI) 670 
between different samples on the same blot then normalised to control) of PFKFB3 (n=3).  (B) 671 
Western blot showing PFKFB3 protein expression levels in THP-1 cells with NOX2 knocked 672 
down (KD) or cells treated with DPI (100nM) for 24 h compared to control (non-mammalian 673 
shRNA) cells.  Lower panel showing relative protein expression of PFKFB3 compared to control 674 
(n=3).  (C) Percentage proliferative change (normalised to control) in THP-1 cells with NOX2 675 
KD (n>3) over 72 h.  (D) Glucose uptake in single cell analysis using 2-NBDG (normalised to 676 
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control) in THP-1 cells with NOX2 KD (n=4) or THP-1 cells treated with 300 mU/mL 677 
PEGylated catalase (Cat; n=6).  (E) Western blot showing PFKFB3 protein expression in 678 
Mv4;11 cells treated with glucose oxidase (GOX) (10 and 20mU/mL for 24 h), which catalyses 679 
production of hydrogen peroxide (H2O2) in cell culture media; (imitating the effect of NOX2-680 
generated ROS production).  Lower panel showing relative protein expression of PFKFB3 681 
compared to control (n=3).  Correlation of PFKFB3 overexpression in Mv4;11 cells treated with 682 
GOX for 24 h on (F) proliferation and (G) glucose uptake using 2-NDBG (n=5).  Actin was used 683 
as a loading control.  Data represents mean±1SD. † denotes p<0.05 analysed by ANOVA with 684 
Tukey’s honestly significance difference.  * denotes p<0.05 analysed by one sample t-test. 685 
Figure 5.  Effect of PFKFB3 overexpression and knock down on proliferation and glucose 686 
uptake in leukemia cells.  (A) Western blot analysis of PFKFB3 protein comparing control and 687 
PFKFB3-overexpression (OE) Mv4;11 cells.  Actin was used as a loading control.  (B) 688 
Percentage proliferation (normalised to control) of Mv4;11 PFKFB3 over-expressed (OE) cells 689 
compared to control (n>3).  (C) Glucose uptake in Mv4;11 PFKFB3-OE cells compared to 690 
control following 72 h (n=3).  Glucose was assayed in the culture media and glucose uptake in 691 
the cell is inversely proportional to the glucose remaining in the media.  The concentration of 692 
glucose in the culture media (starting concentration 25nmol/L) of PFKFB3-OE cells after 24 h 693 
was 15nmol/μL compared with 23nmol/μL in control cells.  (D) Western blot analysis of 694 
PFKFB3 protein comparing control (non-mammalian targeting shRNA control) and PFKFB3 695 
knock down (KD) in THP-1 cells.  Actin was used as a loading control.  (E) Percentage 696 
proliferation (normalised to control) of THP-1 PFKFB3-KD cells compared to control (n>3).  (F) 697 
Glucose uptake in single cell analysis using 2-NBDG (normalised to control) of THP-1 698 
PFKFB3-KD cells compared to control following 24h growth (n=5).  Data represents 699 
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mean±1SD.  † denotes p<0.05 analysed by ANOVA with Tukey’s honestly significance 700 
difference.  *** p<0.005 denotes statistical significance calculated by Student’s t-test calculated.    701 
Figure 6.  ROS induced changes in PFKFB3 expression is mediated via UCP/p-AMPK.  (A) 702 
Normalised log2 expression of HIFA (transcript ID 3567728) mRNA in control HSPC, DPI, N-703 
RASG12D HSPC and N-RASG12D HSPC treated with DPI (100nM).  Box plots represent median 704 
quartile ranges, x represents mean value (n=4).  p-Value calculated by 2-way ANOVA with 705 
Bonferroni multiple testing correction.  (B)(i) Western blot showing expression of HIF-1α in 706 
control THP-1, THP-1 NOX2-KD and THP-1 cells treated with DPI as (A).  As positive 707 
controls, THP-1 cells were treated with CoCl2 as indicated (an inhibitor of HIF-1α degradation 708 
(50)).  HIF-1α recombinant protein were also immunoblotted.  Actin was used as loading control.  709 
(B)(ii) Western blot showing expression of HIF-1α, comparing control THP-1 (non-mammalian 710 
shRNA target) and THP-1 HIF-1α knocked down (KD).  Cells were also untreated or treated 711 
with CoCl2 as above.  (C) Western blot showing expression of PFKFB3 in THP-1 cells knocked 712 
down with HIF1-.  (D) Glucose uptake (normalised to control) of THP HIF-1α KD cells (n=3).  713 
Data represents mean±1SD.  (E) Immunoblot showing PFKFB3, UCP2 and p-AMPK expression 714 
upon 1 h pre-treatment of Mv4;11 cells with the UCP2 inhibitor Genipin (5M) followed by 715 
GOX treatment for 24 h.  (F) Glucose uptake using 2-NBDG (normalised to untreated cells; 716 
control) of Mv4;11 cells treated with GOX (20mU/mL) and / or Genipin (5M) (n=5).  Data 717 
represents mean±1SD.  *** p<0.005 and §p<0.01 denotes statistical significance calculated by 718 
Student’s t-test calculated. 719 
Figure 7.  Targeting PFKFB3 reduces glucose uptake and cell proliferation in AML cells.  720 
Glucose uptake using 2NBDG (normalised to untreated control) in THP-1 cells lines treated with 721 
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(A) 3PO or (B) PFK158 for 24 h.  Vehicle control for 3PO and PFK158 was DMSO 0.05% and 722 
DMSO 0.01% respectively.  Data represents mean±1SD (n>3).  Proliferation (normalised to 723 
control) in THP-1 cells, seeded at 4 x 105/mL treated with (C) 3PO or (D) PFK158.  Vehicle 724 
control for 3PO, DMSO 0.05% (n=6).  Vehicle control for PFK158, DMSO 0.01% (n=6).  (E) 725 
Glucose uptake using 2NBDG (normalised to untreated control) in Mv4;11 cells treated with 726 
inhibitors to PFKFB3 and/or incubated with 10 mU/mL GOX (source of H2O2) (n=3).  (F) 727 
Representative flow cytometric bivariate plots from bone marrow harvested from tibias and 728 
femurs of adult NSG mice (7-10 weeks old) sub-lethally irradiated with 200cGy total body 729 
irradiation 24 h before injection of control THP-1 cells or THP-1 cells where PFKFB3 was KD.  730 
Human cells were distinguished from mouse cells using hCD45-FITC, hCD33-APC and 731 
mCD45-PerCP-Cy5.5 antibodies.  Uninoculated NSG mice were used to control for the analysis 732 
of THP-1 engraftment (n=4) and analysed at week 6.  Data represents mea ±1SD.  † denotes 733 
p<0.05 and represent significantly different groups from control, analysed by ANOVA with 734 
Tukey’s honestly significance difference.  *** p<0.005 denotes statistical significance calculated 735 
by Student’s t-test calculated. 736 







